Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530
Conditions
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Real World CCH Study in Adult Females With Cellulite

NCT04170296
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
11
States / cities
Encino, California • San Diego, California • Solana Beach, California + 8 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

NCT04677712
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
CCH-aaes, Compression, Cold Packs, Arnica Gel, INhance®, PDL
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 2 more
Conditions
Cellulite
Interventions
CBL-514 injection
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Encinitas, California • Encino, California • San Diego, California + 2 more
Conditions
Cellulite
Interventions
40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Encino, California • New York, New York
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
Collagenase Clostridium Histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Santa Monica, California • Coral Gables, Florida + 7 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03428750
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
26
States / cities
Scottsdale, Arizona • Encinitas, California • Long Beach, California + 21 more
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
Collagenase Clostridium Histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • Huntington Beach, California • San Diego, California + 8 more
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 1 more